Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

Benzinga · 1d ago
Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.